昊海生物科技(06826.HK)提名沈紅波為獨立非執行董事候選人
格隆匯12月1日丨昊海生物科技(06826.HK)公吿,根據中國證券監督管理委員會於2023年8月1日發佈的《上市公司獨立董事管理辦法》關於"獨立董事原則上最多在三家境內上市公司擔任獨立董事"規定,為滿足監管要求,同時考慮個人工作精力,郭永清已申請辭任第五屆董事會獨立非執行董事以及在董事會下設各專門委員會中的一切職務(即,審計委員會主席,薪酬與考核委員會成員以及提名委員會成員)。郭永清的辭任將在選舉新獨立非執行董事的議案於股東大會獲通過後生效。
董事會欣然宣佈,提名沈紅波為獨立非執行董事候選人,以填補因郭永清辭任獨立非執行董事而留下的空缺。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.